IREB2 and metabolic dysfunction-associated steatotic liver disease: Considering that IREB2 was experimentally found to affect the expression of the TLR4/NF-κB pathway, we speculate that IREB2 inhibits NAFLD progression by regulating the TLR4/NF-κB pathway.